Charles River Laboratories International Inc.
Charles River Laboratories International, Inc. (CRL)
Overview
Charles River Laboratories International, Inc. is a leading global contract research organization (CRO) that supports the drug discovery, non-clinical development, and safety-testing needs of the pharmaceutical, biotechnology, and medical device industries. Headquartered in Wilmington, Massachusetts, the company was founded in 1947 by veterinarian Henry Foster, who began by breeding laboratory rats on a Virginia farm; it relocated to Wilmington in 1955, expanded internationally starting in 1966, and has operated as a public company on the NYSE (ticker CRL) following periods of private ownership by the Foster family. Charles River is a substantial company by scale, employing roughly 19,700–20,000 people across more than 20 countries and generating about $4.0 billion in revenue in fiscal 2025 — though the company posted a net loss of roughly $144 million that year after several years of consistent profitability, and its market capitalization (around $14 billion, up sharply over the past year) reflects a significant rebound in investor sentiment following a difficult stretch for the CRO and life-sciences-tools sector.
What They Do & How They Make Money
Charles River essentially rents out scientific expertise, laboratory infrastructure, and specialized biological materials to pharmaceutical and biotech companies that need to discover, test, and manufacture new drugs but don't want to build and staff all of that capability in-house. Its revenue comes primarily from fee-for-service contracts: pharmaceutical and biotech clients (ranging from the largest global drugmakers to small, venture-funded biotech startups) pay Charles River to breed and supply purpose-bred research animals, run preclinical toxicology and safety studies required before a drug can enter human trials, provide outsourced laboratory and vivarium space, and perform quality-control testing and contract manufacturing support for biologics and cell/gene therapies. Because Charles River sits at a critical, regulator-mandated checkpoint in the drug-development pipeline — safety and toxicology testing is legally required before clinical trials can begin — its business is closely tied to the overall health of pharmaceutical and biotech R&D spending, and in particular to the funding environment for early-stage biotech companies, since smaller, venture-backed biotechs are a meaningful and often more cyclical source of demand than large pharma.
Business Segments
Charles River organizes its operations into three reportable segments:
- Research Models and Services (RMS) — The company's founding business, producing purpose-bred rodents (rats and mice) and other research models used throughout the pharmaceutical and academic research industries, along with related research support services such as genetically engineered model services and research model licensing.
- Discovery and Safety Assessment (DSA) — The company's largest segment, providing outsourced drug discovery support, preclinical toxicology, pathology, and vivarium (laboratory animal housing) services that pharmaceutical and biotech companies need to advance drug candidates toward clinical trials. This segment does the core "safety testing" work that regulators require before human trials can begin.
- Manufacturing Solutions — Quality control testing services (including microbial and sterility testing) for pharmaceutical and consumer products, along with contract development and manufacturing services increasingly focused on cell therapy, gene therapy, and other advanced biologics — an area Charles River has built out significantly through acquisitions such as Cognate BioServices ($875 million, 2021) and Citoxlab (€448 million, 2019).
Discovery and Safety Assessment is generally the company's largest segment by revenue, reflecting the scale and duration of preclinical safety programs, while Manufacturing Solutions has been the fastest-growing segment historically as Charles River has pushed further into higher-value cell and gene therapy support services; RMS, while smaller, remains a strategically important, high-margin franchise given the company's decades-long position as a leading global supplier of research models.
Competitors
Charles River competes across the fragmented but consolidating global CRO and life-sciences services industry:
- Large diversified CROs: IQVIA, ICON plc, and Labcorp (which also runs a large drug development/CRO business) compete broadly across preclinical and clinical research services.
- Preclinical/safety-assessment specialists: Envigo (now part of Inotiv following a 2021 merger) is one of Charles River's most direct competitors in research models and toxicology testing.
- Manufacturing/CDMO competitors: companies such as Catalent, Lonza, and other contract development and manufacturing organizations compete in the biologics, cell, and gene therapy manufacturing space that Charles River's Manufacturing Solutions segment targets.
- In-house pharma R&D departments: large pharmaceutical companies with substantial internal toxicology and safety-testing capabilities represent a form of indirect competition (the "build vs. buy" decision), and internal capacity expansion by big pharma can pressure CRO demand.
Competitive Position
Charles River's competitive moat rests on decades of accumulated scientific expertise, regulatory relationships, specialized infrastructure (including purpose-bred animal colonies and accredited laboratory facilities), and a broad, integrated service offering that lets it support drug programs from early discovery through manufacturing — a "one-stop shop" positioning that larger pharma clients value for program continuity and smaller biotech clients value for capability access without heavy capital investment. Its long operating history as a global leader in laboratory animal breeding and preclinical safety testing gives it scale advantages and regulatory credibility that are difficult for new entrants to replicate quickly.
That said, the business is significantly exposed to cyclicality in biotech funding: the 2023–2025 period saw a pronounced slowdown in venture capital funding for early-stage biotech, which reduced demand for preclinical services and research models industry-wide, contributing to Charles River's revenue plateau (from $4.13 billion in 2023 down modestly through 2025) and its swing to a net loss in fiscal 2025 — a period during which the company also undertook "portfolio refinement" (its own characterization) alongside broader cost and capacity adjustments. More recently, the company has signaled improving momentum, raising full-year guidance in 2026 on the back of strong Q2 results and improved biopharma demand, and management has continued pursuing new collaborations (such as partnerships with Medigen Vaccine Biologics and Arovella Therapeutics) to diversify its client base. The company also carries ongoing reputational and regulatory risk tied to animal welfare controversies — including 2023 protests over a planned export of roughly 1,000 endangered long-tailed macaques to Cambodia, and broader, recurring criticism of its use of laboratory animals including dogs, non-human primates, and horseshoe crabs — which pose both regulatory compliance risk and brand/ESG risk with certain investors and the public. Longer term, secular trends such as growing adoption of non-animal testing alternatives (organ-on-chip, in silico modeling) represent both a risk to its traditional animal-model business and an opportunity the company is investing to capture as testing methodologies evolve.